Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02057575 · ClinicalTrials.gov registry record · Phase 2
Study Assessing Safety and Efficacy of PG324 Ophthalmic Solution in Patients With Elevated Intraocular Pressure
A Phase 2 study, sponsored by Aerie Pharmaceuticals.
- Completed
- Registry status
- Phase 2
- Development phase
- 298
- Enrollment target
NCT02057575: Completed Phase 2 study, sponsored by Aerie Pharmaceuticals.
NCT02057575 is a Phase 2 study that has completed, run by Aerie Pharmaceuticals. The registered enrollment target is 298 participants, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (124% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02057575, a Phase 2 study, has completed, sponsored by Aerie Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 298 participants
- Enrollment target
Study Summary
To evaluate the ocular hypotensive efficacy of PG324 ophthalmic solution relative to its individual components in patients with open angle glaucoma or ocular hypertension.
Primary Outcome
The primary efficacy endpoint was the mean diurnal IOP across subjects within treatment group at Day 29.
Interventions
- DRUG PG324 Ophthalmic Solution 0.01%
- DRUG PG324 Ophthalmic Solution 0.02%
- DRUG Netarsudil (AR-13324) Ophthalmic Solution 0.02%
- DRUG Latanoprost Ophthalmic Solution 0.005%
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 298 participants |
| Start Date | 2014-01 |
| Est. Completion | 2014-06 |
| Phase | Phase 2 |
What the finished NCT02057575 record still lists
NCT02057575 is an interventional study that assigns participants to a tested intervention. The registered 298 participants enrollment target is mid-sized for trials with a published cap, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (124% higher).
The record links to 0 conditions, and to 4 interventions - of which PG324 Ophthalmic Solution 0.01% is the first listed.
NCT02057575 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02057575 about?
NCT02057575 is a clinical study titled "Study Assessing Safety and Efficacy of PG324 Ophthalmic Solution in Patients With Elevated Intraocular Pressure". To evaluate the ocular hypotensive efficacy of PG324 ophthalmic solution relative to its individual components in patients with open angle glaucoma or ocular hypertension.
What is the current status of trial NCT02057575?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 298 participants. The study started on 2014-01. Estimated completion is 2014-06.
What interventions are being tested in trial NCT02057575?
The interventions under investigation include: PG324 Ophthalmic Solution 0.01% (DRUG), PG324 Ophthalmic Solution 0.02% (DRUG), Netarsudil (AR-13324) Ophthalmic Solution 0.02% (DRUG), Latanoprost Ophthalmic Solution 0.005% (DRUG).
Who is sponsoring clinical trial NCT02057575?
This trial is sponsored by Aerie Pharmaceuticals, which has 32 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02057575's enrollment target sits among peer trials
298 188th of 2000 higher than 1,813 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06305624 · 298 participants · NA
Implementation of Mobile-based Programs for Alcohol Cessation in Treatment of Alcohol-associated Liver Disease
- NCT06754215 · 298 participants · NA
Smoking Cessation Intervention Development for Homeless Youth
- NCT06780111 · 298 participants · Phase 1
Substudy 06E: Umbrella Study of Combination Therapies in Esophageal Cancer (MK-3475-06E/KEYMAKER-U06)
- NCT07209358 · 298 participants · NA
EDX110 Randomized Control Trial for Treatment of DFUs
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia